β-catenin has traditionally been an “undruggable” target, despite preclinical studies elucidating the molecular and metabolic addiction to β-catenin oncogenic signaling in CTNNB1-mutated HCC.20–23 Thus, β-catenin is a prime target for precision therapy. The gene discussed is CTNNB1; the disease is hepatocellular carcinoma.